Racotumomab

Research use only, not for human use.

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is a mouse γ-type anti-recombinant antibody that specifically induces an antibody response against Neu-glycolyl GM3 ganglioside (NeuGcGM3), overexpressed in various solid tumors.

Racotumomab (Anti-Human NGcGM3 Recombinant Antibody) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer.

Racotumomab induces a specific humoral and cellular immune response against the NeuGcGM3 ganglioside present in tumor cells, stimulating the cell death.

Racotumomab (50 μg/dose, i.p.) together with Keyhole limpet hemocyanin (KLH) inhibits tumor growth in F3II cell (s.c.) mammary tumor mice model.Racotumomab (50 μg/dose, s.c.) together with Pemetrexed (100 mg/kg) is highly effective against lung nodules in 3LL cell (s.c.) mice xenograft.Racotumomab (50-200 μg/dose, s.c.) shows no significant antitumor effect in 3LL cell (s.c.) mice xenograft.Animal Model:3LL cell (s.c.) mice xenograftDosage:50 μg/dose, together with Pemetrexed (100 mg/kg)Administration:Subcutaneous injection (s.c.)Result:Reduced lung nodules.

——

Others

Other Targets

Others

——

——

946832-34-4

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years